Hepatitis C Virus Infection among Hematopoietic Cell Transplant Donors and Recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations

Abstract

2016-11-02T18:49:00

Universal screening for hepatitis C: A needed approach in patients with haematologic malignancies

“…To date, there are no large studies on the prevalence of anti‐HCV and the optimal HCV screening strategy in patients with haematologic malignancies and hematopoietic cell transplant (HCT) recipients. On the basis of the limited available evidence, professional societies such as the American Society for Blood and Marrow Transplantation and the European Conference on Infection in Leukaemia recommend universal screening of such patients. We aimed to determine the prevalence of anti‐HCV and to compare the effectiveness of universal HCV screening vs risk factor‐based and 1945‐1965 birth cohort‐based screening at the largest tertiary cancer centre in the United States.…”

Hepatitis C Virus Infection in Patients Undergoing Hematopoietic Cell Transplantation in the Era of Direct-Acting Antiviral Agents

“…9 However, such recommendations are based mainly on consensus opinion of experts on the standard-of-care, as there is a major lack of data regarding the management of HCV in infected HCT recipients.…”

Treatment of hepatitis C in a pediatric patient using simeprevir and sofosbuvir immediately after an umbilical cord blood transplantation

“…9 DAAs have the potential to significantly change the natural course of HCV infection in HSCT recipients. 10 Although new guidelines for the diagnosis and management of HCV infection in HSCT recipients are becoming available, information regarding DAAs in pediatric patients undergoing HSCT remains sparse. 7,10 We present a case of an HCV-infected pediatric patient who was treated with simeprevir and sofosbuvir immediately following an umbilical cord blood transplantation.…”

“…However, current recommendations for HCV treatment for HSCT recipients are based on clinical trials involving other patient populations. 7,10 As more data regarding HCV treatment are reported, optimal recommendations for HSCT recipients will likely develop. The HCV guidance from the American Association for the Study of Liver Disease and Infectious Disease Society of America recommend choosing the appropriate drug combination based on host and viral factors.…”

“…Furthermore, drug levels (cyclosporine) should be monitored closely since protease inhibitors (simeprevir) may increase chemotherapy or immunosuppressive agents while the polymerase inhibitors (sofosbuvir) are affected by immunosuppressive agents such as cyclosporine, tacrolimus and sirolimus. 10 Data regarding the use of DAAs in treatment of pediatric HSCT recipients infected with HCV are very limited. We report that simeprevir and sofosbuvir were well tolerated and led to a sustained viral response in a pediatric patient undergoing umbilical cord blood transplantation.…”